For example, combining navitoclax with the histone deacetylase (HDAC) inhibitor vorinostat has shown potential in overcoming resistance in SCLC cell lines by promoting apoptosis through the modulation of key apoptotic proteins, like Noxa and BIM, even in cells that are resistant to navitoclax alone [255]. Here, HDAC9 is linked to small cell lung carcinoma.